Gentofte Hospital

At Gentofte Hospital the cardiology unit is investigating novel approaches to improve outcomes for patients with heart failure with preserved ejection fraction and those living with atrial fibrillation, aiming to assess both efficacy and safety of emerging therapies.

• Evaluating colchicine’s impact on health status in HFpEF
• Comparing asundexian with standard anticoagulant apixaban for stroke prevention
• Assessing bleeding risk and overall benefit‑risk profile of new oral anticoagulants

The program involves 30 investigators and supports six active trials, reflecting the department’s commitment to advancing cardiovascular care in Denmark.

Research in the respiratory department targets chronic lung conditions such as chronic obstructive pulmonary disease and fibrotic lung disease, focusing on innovative treatments and immune‑based strategies.

• Live‑vaccine induction of trained immunity to lower systemic inflammation in COPD
• Long‑term safety and tolerability of inhaled treprostinil for IPF/PPF patients
• Exploring novel inhaled therapies to improve lung function and quality of life

These studies aim to expand therapeutic options for patients with severe respiratory disorders while ensuring rigorous safety monitoring.

The site examines fundamental cellular processes that drive disease, including how cells respond to pharmacologic interventions in both cardiac and pulmonary contexts.

• Investigation of cellular pathways underlying trained immunity after vaccination
• Mechanistic studies of colchicine’s effect on cardiomyocyte function
• Cellular response profiling to inhaled treprostinil in fibrotic lung tissue

By linking cellular insights to clinical outcomes, the research supports precision medicine initiatives across multiple therapeutic areas.

A key focus is the modulation of the immune system, assessing how interventions shape innate and adaptive responses in diseases like COPD and atrial fibrillation.

• Characterization of innate immune changes following live‑vaccine exposure in COPD patients
• Monitoring immune safety signals during anticoagulant therapy with asundexian
• Evaluating systemic inflammation markers as predictors of treatment success

These investigations aim to harness immune mechanisms to improve disease management and reduce adverse events.